The first therapeutic cancer vaccine is approved

Historical milestone — this page describes an event dated 2010. It is not current breaking news.

Two very different things called a vaccine

Most vaccines prevent an infection. A treatment vaccine does something else: it is given to someone who already has cancer, to teach their immune system to attack it.

NCI draws the line clearly. Prevention vaccines work against something that causes cancer, such as HPV. Treatment vaccines work against cancer cells directly.

The idea rests on tumor-associated antigens. These are substances that cancer cells carry and normal cells either lack or carry at much lower levels. A treatment vaccine tries to train the immune system to recognize one of them.

In 2010 the FDA approved PROVENGE, generic name sipuleucel-T, made by Dendreon Corporation under license number BL 125197. It was the first therapeutic cancer vaccine cleared in the United States.

What is actually made

Sipuleucel-T is not a shot off a shelf. It is manufactured separately for each person.

NCI classes it as a dendritic cell vaccine. Dendritic cells are the immune system's messengers: they pick up an antigen and present it to T cells, which then go hunting.

Immune cells are collected from the person's blood by leukapheresis, a process that filters out one cell type and returns the rest. Those cells are exposed in a laboratory to a fusion protein, then washed and infused back into the same person.

The fusion protein joins two pieces. One is prostatic acid phosphatase, a protein found on prostate cancer cells. The other is GM-CSF, an immune signal that activates the cells being treated. The product is given intravenously.

Who it was approved for

The FDA's indication is narrow: asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer.

Unpacked, that is three conditions at once. The cancer has spread beyond the prostate. It has kept growing despite hormone treatment that lowers testosterone, which is what "castrate-resistant" means. And the person has few or no symptoms from it.

NCI states the same three requirements in plain language on its treatment vaccines page.

The trial

The evidence was a double-blind, placebo-controlled, multicenter phase 3 trial. It randomly assigned 512 men in a 2:1 ratio: 341 to sipuleucel-T and 171 to placebo, each given intravenously every two weeks for three infusions.

The primary endpoint was overall survival, which is the endpoint that matters most and is hardest to move.

Median survival was 25.8 months with sipuleucel-T and 21.7 months with placebo, a difference of 4.1 months. The hazard ratio for death was 0.78, with a 95% confidence interval of 0.61 to 0.98 and a p-value of 0.03. That is a 22% relative reduction in the risk of death over the study period.

Survival at 36 months was 31.7% against 23.0%.

The strange part of the result

Time to objective disease progression was similar in both groups.

That is unusual and worth sitting with. The treatment did not visibly delay the cancer's growth on scans, yet people lived longer. Immune responses to the target antigen were seen in men who received it.

Most cancer drugs are judged first on whether tumors shrink or stop growing. This one moved the survival curve without moving that measure, which is part of why it was both influential and argued over.

Side effects

The adverse events reported more often with sipuleucel-T than placebo were chills, fever, and headache.

NCI's broader page on treatment vaccines lists the flu-like pattern these products can cause: fever, chills, weakness, dizziness, nausea or vomiting, muscle and joint aches, fatigue, headache, trouble breathing, and blood pressure that runs low or high. Severe allergic reactions are possible.

NCI also names one specific serious risk for this product. Sipuleucel-T can cause stroke.

When to get checked

Prostate cancer screening is not a simple yes. It is a decision to make with a clinician, weighing early detection against finding cancers that would never have caused harm. Our pages on the PSA test and prostate cancer screening lay out both sides.

Symptoms are a separate matter and deserve their own appointment. NCI says to check with a doctor about:

• Trouble starting the flow of urine.
• Frequent urination, especially at night.
• Trouble emptying the bladder completely.
• A weak or interrupted, stop-and-go, flow of urine.

NCI adds that prostate cancer found at an advanced stage may bring pain in the back, hips, or pelvis that does not go away. It may also bring shortness of breath, deep fatigue, a fast heartbeat, dizziness, or pale skin, all caused by anemia.

Our overview of prostate cancer covers what happens after a raised PSA result.

The wider picture

The American Cancer Society projects about 333,830 new prostate cancer diagnoses and 36,320 deaths in the United States in 2026, and SEER, the NCI surveillance program, carries those projections. Five-year relative survival across all stages was 98.2% for people diagnosed from 2016 through 2022.

That very high figure hides the group this approval concerns. For the same 2016–2022 cohort, SEER records 69% of prostate cancers found while local and 14% in nearby nodes, both at 100.0% five-year relative survival. Nine percent are found after distant spread, where five-year relative survival is 40.1%.

Registry averages describe populations across years. They do not describe one person.

What to keep in perspective

A 4.1-month difference in median survival is a real, measured effect and a modest one. Both halves of that sentence are true and neither should be dropped.

The approval covered one narrow situation only. It says nothing about localized prostate cancer, about hormone-sensitive disease, or about men with significant symptoms.

The manufacturing is also its own constraint. A product built individually from a person's own cells needs an apheresis appointment, a laboratory slot, and a fixed schedule, which is a different kind of demand from a prescription.

And a 2010 milestone describes the field as it stood then. It is history, not a treatment recommendation for anyone reading now.

Sources

• FDA: PROVENGE (sipuleucel-T), STN BL 125197
• Kantoff PW et al., Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med 2010 (NCBI E-utilities record)
• NCI: Cancer Treatment Vaccines
• NCI PDQ: Prostate Cancer Treatment (Patient Version)
• NCI SEER Cancer Stat Facts: Prostate Cancer

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.